Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Articles|March 4, 2022
Daily Medication Pearl: Upadacitinib (Rinvoq)
Author(s)Saro Arakelians, PharmD
Advertisement
Medication Pearl of the Day: Upadacitinib (Rinvoq)
Indication: Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.
Insight:
- Dosing: The recommended dosage of Rinvoq is 15 mg once daily.
- Dosage forms: Extended-release tablets 15 mg and 30 mg.
- Adverse events: Adverse reactions (≥ 1%) were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, and acne.
- Mechanism of action: JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
- Manufacturer: AbbVie
Sources:
Advertisement
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
A PharmD candidate reflects on the small, evidence-backed daily habits that helped her thrive—not just survive—through pharmacy school's most demanding years.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5